Michael Rogers
Director/Board Member at AKEBIA THERAPEUTICS, INC.
Net worth: 87 819 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| John Butler | M | 59 | 11 years | |
| Jay Duker | M | 66 | 8 years | |
| Nicole Hadas | F | 51 | 11 years | |
| Steven Gilman | M | 71 | 8 years | |
| Nancy Lurker | F | 66 | 8 years | |
| Göran Albert Ando | M | 75 | 6 years | |
| Michael Weiss | M | 58 | 11 years | |
| Ron I. Honig | M | - | 6 years | |
| Michel Dahan | M | 45 | 11 years | |
| Cynthia Smith | F | 55 | 6 years | |
| Ronald Frieson | M | 65 | 3 years | |
| John Landis | M | 71 | 6 years | |
| Myles Wolf | M | 53 | 4 years | |
| David Guyer | M | 64 | 5 years | |
| LeAnne Zumwalt | F | 65 | 3 years | |
| Adrian Adams | M | 73 | 6 years | |
| Mercedes Carrasco | F | - | - | |
| Maria Petrini | F | - | 1 years | |
| Carolyn Rucci | F | - | 3 years | |
| Meredith Bowman | F | - | 2 years | |
| Christian Barnes | M | - | - | |
| Leonard Dove | M | 51 | 2 years | |
| Jody Gould | M | - | 3 years | |
| Tracey Vetterick | F | - | 2 years | |
| Nicholas Grund | M | 54 | - | |
| George Avgerinos | M | 71 | 11 years | |
| Steven Burke | M | 63 | 5 years | |
| Michael Rabinowitz | M | - | - | |
| Richard Malabre | M | 63 | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Glenn L. Cooper | M | 71 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 20 years |
| Michael Tarnok | M | 69 | 9 years | |
| Robyn Hunter | F | 62 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 14 years |
| Jodie Morrison | F | 48 | 4 years | |
| Michael Heffernan | M | 59 | 6 years | |
| Charles H. Abdalian | M | 73 | 1 years | |
| Bobby Sandage | M | 70 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 21 years |
| Mark Enyedy | M | 60 | 4 years | |
| Noah Beerman | M | 62 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 15 years |
| Gregory Madison | M | 57 | 4 years | |
| Regina Marek | F | 55 | 3 years | |
| Raymond Tabibiazar | M | 53 | - | |
| Paul Ashton | M | 63 | 11 years | |
| Stéphane Bancel | M | 51 | 5 years | |
| Scott A. Holmes | M | 50 | 3 years | |
| Jason Amello | M | 55 | 7 years | |
| David Spellman | M | 48 | 3 years | |
| Harlan Weisman | M | 71 | 1 years | |
| David Mazzo | M | 67 | 15 years | |
| Pieter Muntendam | M | 65 | 8 years | |
| Lori Freedman | F | 57 | 10 years | |
| Robert Morales | M | 57 | 7 years | |
| Dale Ritter | M | 73 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 18 years |
| Caroline B. Manogue | F | 55 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | - |
| Adrian L. Rabinowicz | M | - | 6 years | |
| Maxine Gowen | M | 66 | 7 years | |
| Marty Nazzaro | M | - | - | |
| Leonard S. Ross | M | 74 | 13 years | |
| Kristine Peterson | F | 64 | 3 years | |
| Michael Clayman | M | 72 | 4 years | |
| Amy Sullivan | F | 54 | 4 years | |
| Hong Guo | M | - | - | |
| Kevin M. Jordan | M | - |
Lehman Brothers, Inc.
 Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 2 years |
| Eric Bouvier | M | 63 | 2 years | |
| Duane Nash | M | 53 | 5 years | |
| Daniel Paul Regan | M | 60 | 5 years | |
| Bruce R. Lakefield | M | 80 |
Lehman Brothers, Inc.
Lehman Brothers, Inc. Investment Banks/BrokersFinance A subsidiary of Lehman Brothers Holdings, Inc., Lehman Brothers, Inc. is a broker/dealer headquartered in New York City. They provide global equity and fixed research. The equity research department covers more than 100 sectors. They use a fundamental, quantitative, strategic and tactical research approach. In addition to these Lehman has also developed special products, such as 10 uncommon values and 10 uncommon eurovalues. | 4 years |
| Brian Adams | M | 50 | 4 years | |
| John Hohneker | M | 64 | 3 years | |
| Michael Wyzga | M | 69 | 4 years | |
| Dhaval Desai | M | - | 4 years | |
| Peter Savas | M | 75 | 8 years | |
| Eric Zhang | M | 43 | 5 years | |
| Rudy Howard | M | 67 | 2 years | |
| Violetta Cotreau | F | 51 | 2 years | |
| Nancy Wysenski | F | 66 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | - |
| Wyche Fowler | M | 83 | 10 years | |
| Muneer Satter | M | 63 | 5 years | |
| David Barrett | M | 48 | - | |
| Xiao Qin Lu | M | 49 | 5 years | |
| Ronald Renaud | M | 55 | 4 years | |
| Stephen J. Hoffman | M | 70 | 2 years | |
| David P. Holveck | M | 79 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | - |
| Mark S. Butler | M | 77 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 16 years |
| Thomas Forest Farb | M | 67 |
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | 3 years |
| Lora L. Pike | F | - | - | |
| Brian Posner | M | 62 | 3 years | |
| Ronald Eastman | M | 71 | 4 years | |
| Kevin Cameron | M | 64 | 11 years | |
| Sigurd Kirk | M | 57 | 3 years | |
| Tai Ching Ho | M | 62 | 3 years | |
| Jack Kaye | M | 80 | 10 years | |
| Gary Gemignani | M | 58 | 1 years | |
| Ellen Snow | F | - | 1 years | |
| Douglas Godshall | M | 59 | 9 years | |
| Cheryl L. Cohen | F | 58 | 3 years | |
| Amato Giaccia | M | 65 | 6 years | |
| Paul Hopper | M | 68 | 6 years | |
| Joseph Feczko | M | 75 | 6 years | |
| Scott Canute | M | 63 | 3 years | |
| James Barry | M | 64 | 4 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Michael Rogers
- Personal Network
